Equol exerts a protective effect on postmenopausal osteoporosis by upregulating OPG/RANKL pathway

Phytomedicine. 2023 Jan:108:154509. doi: 10.1016/j.phymed.2022.154509. Epub 2022 Oct 18.

Abstract

Backgroud: Estrogen deficiency is the leading cause of postmenopausal osteoporosis(PMOP) and phytoestrogens soy isoflavones (SI) have been shown to improve PMOP. Equol (Eq), an in vivo metabolite of phytoestrogens soy isoflavones (SI), has a more stable structure and stronger biological activity than its parent compound and has the greatest estrogenic activity. However, there are few studies on the therapeutic effect of Eq on PMOP.

Purpose: To explore the therapeutic effect and mechanisms of Eq on POMP.

Methods: Osteoblast-like cells ROS1728 were cultured with different doses of Eq, estradiol (E2), separately. The effect of Eq on the proliferation, apoptosis, cell cycle of osteoblasts were detected by CCK-8 and flow cytometry, and the expression of OPG/RANK/RANKL signaling pathway of osteoblasts was detected by Quantitative real-time PCR (qRT-PCR) and Western blot (WB), and RNA silencing technology were carried out to explore the receptors through which Eq plays a role. Then PMOP rat model was established and treated by Eq or E2 to further verification of the effect and mechanism of Eq on PMOP.

Result: Eq promoted the proliferation and inhibited the apoptosis of osteoblasts and increased the proportion of osteoblasts in the S phase and G2/M phase in a dose-dependent manner. Mechanistically, Eq treatment upregulated the expression of OPG and OPG/RANKL ratio in osteoblasts and this regulatory effect was mainly mediated through the ERβ receptor. Furthermore, in vivo study, Eq improved microstructure and BMD of the femur of PMOP rat model, which imitated the osteoprotective effect of E2. Moreover, the Eq or E2 treatment increased serum levels of Ca, 1,25(OH)2D3, bone Gla-protein(BGP), and Type I procollagen (PC1), and reduced serum levels of phosphorus (P), parathyroid hormone(PTH), pyridinol (PYD), tartrate-resistant acid phosphatase (TRAP) and urinary level of deoxypyridinoline (DPD) in the treatment OVX group compared with the untreated OVX group. Meanwhile, Eq or E2 markedly induced the mRNA and protein expression of OPG and OPG/RANKL ratio.

Conclusion: Eq can combine with ERβ and exert a protective effect on PMOP by upregulating OPG/RANKL pathway.

Keywords: Equol; OPG/RANK/RANKL; Osteoblast; Postmenopausal osteoporosis.

MeSH terms

  • Animals
  • Equol / metabolism
  • Equol / pharmacology
  • Estrogen Receptor beta / metabolism
  • Female
  • Humans
  • Osteoblasts
  • Osteoporosis, Postmenopausal* / drug therapy
  • Osteoporosis, Postmenopausal* / prevention & control
  • Osteoprotegerin / metabolism
  • Phytoestrogens / pharmacology
  • RANK Ligand / metabolism
  • Rats

Substances

  • Osteoprotegerin
  • Equol
  • Estrogen Receptor beta
  • Phytoestrogens
  • RANK Ligand